LEADER 01070nam0-22003491--450- 001 990006183880403321 005 20070514131823.0 035 $a000618388 035 $aFED01000618388 035 $a(Aleph)000618388FED01 035 $a000618388 100 $a20000112d1959----km-u0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $a<>categoria dell'utilità nel pensiero di Benedetto Croce$fLanfranco Mossini 210 $aMilano$cGiuffrè$d©1959 215 $a472 p.$d24 cm 225 1 $aPubblicazioni della Facoltà di giurisprudenza$fUniversità di Parma$v10 676 $a195$v20$zita 700 1$aMossini,$bLanfranco$0192242 702 1$aCroce,$bBenedetto$f<1866-1952> 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990006183880403321 952 $aUniv. 151 (10)$b85438*$fFGBC 952 $aUniv. 151 (10 bis)$b26013*$fFGBC 952 $aXI C M 40$fDFD 959 $aDFD 959 $aFGBC 996 $aCategoria dell'utilità nel pensiero di Benedetto Croce$9646546 997 $aUNINA LEADER 03089nam 2200469z- 450 001 9910261144503321 005 20210211 035 $a(CKB)4100000002484647 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/42248 035 $a(oapen)doab42248 035 $a(EXLCZ)994100000002484647 100 $a20202102d2016 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBiomarkers of Alzheimer's Disease: The Present and the Future 210 $cFrontiers Media SA$d2016 215 $a1 online resource (218 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-041-4 330 $aAlzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders and loss of functional autonomy. AD represents the main cause of dementia and has become a major public health issue. In addition, the number of patients suffering from AD is growing rapidly as the population ages worldwide. Memory impairment is usually the earliest clinical and core symptom of this disease. The diagnosis at a late clinical stage is relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms of optimal medical and social care. The actual interest of the scientific head-ways is to optimize the diagnosis in prodromal stage of the disease and to propose personalized therapeutic solutions to individual patients. New revised AD diagnostic criteria include early alteration of cerebrospinal fluid (CSF) biomarkers: decrease of amyloi?d peptides (Aß42), and increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of CSF biological biomarkers for the diagnosis of AD is a major step towards the "molecular" diagnosis and follow-up of the disease. Many issues are however still subject of debate. This e-book provides a comprehensive overview of the state of the art of fluid biomarkers for AD, e.g. which novel biomarkers should be implemented in clinical practice for diagnosis or for monitoring treatment or side effects, which ones are new for AD or related dementias or what is the potential of peripheral blood markers. Moreover, the e-Book provides practical guidelines how to optimally and efficiently develop and validate novel biomarker assays, and to document and control pre-analytical variation. 517 $aBiomarkers of Alzheimer's Disease 606 $aNeurosciences$2bicssc 610 $aAlzheimer 610 $abiomarkers 610 $aBlood 610 $aCSF 610 $aDementias 610 $adiagnosis 610 $adiscovery 610 $amethods 610 $aNeurochemistry 610 $aValidation 615 7$aNeurosciences 700 $aTeunissen$b Charlotte E$4auth$01371814 702 $aLehmann$b Sylvain$f1965-$4auth 906 $aBOOK 912 $a9910261144503321 996 $aBiomarkers of Alzheimer's Disease: The Present and the Future$93401455 997 $aUNINA